CompanyGraph
At a glance
- Depends onDownstream position: depends on 11 industries, supplies 6
- ScaleMarket cap is $1.61B, above the global median of $1.18B
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
10.77BCNY1.61B · vs all stocks (USD)
Revenue (TTM)
397.12MCNY59.23M · vs all stocks (USD)
Profit Margin
-10.69%Beta
-0.1530xvs all stocks
52-Week Change
4.08%vs all stocks
Market Capitalization
10.77BCNY1.61B · vs all stocks (USD)
Enterprise Value
6.81BCNY1.02B · vs all stocks (USD)
Forward P/E
21.03xPrice to Sales (TTM)
27.03xPrice to Book (MRQ)
4.08xEnterprise to Revenue
17.14xGross Margin
60.55%Profit Margin
-10.69%Operating Margin
0.66%Return on Assets (TTM)
-1.30%Return on Equity (TTM)
-3.90%Revenue (TTM)
397.12MCNY59.23M · vs all stocks (USD)
Revenue per Share (TTM)
0.3490CNYUpdated Sep 19, 2026Quarterly Revenue Growth
21.50%Gross Profit (TTM)
239.83MCNY35.77M · vs all stocks (USD)
EBITDA (TTM)
20.12MCNY3.00M · vs all stocks (USD)
Net Income (TTM)
-42.45MCNY-6.33M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
13.90%Operating Cash Flow (TTM)
-64.17MCNY-9.57M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-227.70MCNY-33.96M · vs all stocks (USD)
Payout Ratio
0.00%Minority Interest (Equity)
-51.39MCNYFY2025 · Dec 31, 2025Revenue
378.11MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
140.32MCNYFY2025 · Dec 31, 2025Gross Profit
237.79MCNYFY2025 · Dec 31, 2025Operating Income
-27.89MCNY-4.16M · vs all stocks (USD)
Pre-tax Income
-77.60MCNYFY2025 · Dec 31, 2025Income Tax Expense
1.44MCNYFY2025 · Dec 31, 2025Net Income
-79.05MCNYFY2025 · Dec 31, 2025EBIT
-47.23MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
20.12MCNYFY2025 · Dec 31, 2025Research & Development
11.00MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
183.72MCNYFY2025 · Dec 31, 2025Other Operating Expenses
10.42MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
417.45KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
30.37MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.0919CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.0919CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
880.19MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
880.19MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-79.05MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-1.84MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-104.88MCNYFY2025 · Dec 31, 2025Free Cash Flow
-108.84MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
37.48MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-79.05MCNYFY2025 · Dec 31, 2025Other Non-cash Items
30.86MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-50.94MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-5.75MCNYFY2025 · Dec 31, 2025Capital Expenditures
-3.97MCNYFY2025 · Dec 31, 2025Purchase of Investments
-31.46MCNYFY2025 · Dec 31, 2025Sale of Investments
119.68MCNYFY2025 · Dec 31, 2025Other Investing Activity
426.99KCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
84.68MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00CNYFY2025 · Dec 31, 2025Long-term Debt Payments
-143.28MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-10.53MCNYFY2025 · Dec 31, 2025Other Financing Charges
-11.25MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-165.06MCNYFY2025 · Dec 31, 2025Shares Outstanding
1.76BSharesUpdated Sep 19, 2026Float Shares
852.34MSharesUpdated Sep 19, 2026% Held by Insiders
52.04%vs all stocks
% Held by Institutions
7.60%vs all stocks
Total Cash (MRQ)
1.65BCNY246.63M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.18CNYUpdated Sep 19, 2026Total Debt (MRQ)
6.80MCNY1.01M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0034xCurrent Ratio (MRQ)
5.04xBook Value per Share (MRQ)
1.50CNYUpdated Sep 19, 2026Total Assets
819.95MCNY122.30M · vs all stocks (USD)
Total Current Assets
275.35MCNYFY2025 · Dec 31, 2025Total Liabilities
848.20MCNYFY2025 · Dec 31, 2025Total Non-current Assets
544.60MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
46.64MCNYFY2025 · Dec 31, 2025Total Current Liabilities
801.56MCNYFY2025 · Dec 31, 2025Cash
37.48MCNYFY2025 · Dec 31, 2025Cash Equivalents
38.11MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
75.60MCNYFY2025 · Dec 31, 2025Accounts Receivable
45.23MCNYFY2025 · Dec 31, 2025Inventory
38.83MCNYFY2025 · Dec 31, 2025Accounts Payable
107.92MCNYFY2025 · Dec 31, 2025Short-term Debt
87.43MCNYFY2025 · Dec 31, 2025Other Current Liabilities
194.81MCNYFY2025 · Dec 31, 2025Long-term Debt
5.88MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
26.35MCNYFY2025 · Dec 31, 2025Common Stock (Book)
416.69MCNYFY2025 · Dec 31, 2025Retained Earnings
-1.13BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
-28.25MCNY-4.21M · vs all stocks (USD)
52-Week Low
4.58CNYUpdated Sep 19, 202652-Week High
9.48CNYUpdated Sep 19, 202652-Week Change
4.08%vs all stocks
Beta
-0.1530xvs all stocks
50-Day MA
6.53CNYUpdated Sep 19, 2026200-Day MA
6.85CNYUpdated Sep 19, 2026Avg 10-Day Volume
8.55MSharesUpdated Sep 19, 2026Avg 30-Day Volume
18.26MSharesUpdated Sep 19, 2026Diluted EPS (TTM)
-0.0500CNYUpdated Sep 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.61Profit Margin: -0.11
Supply Chain
Downstream position: depends on 11 industries, supplies 6Notable
Outgoing: 6.00Incoming: 11.00
High connectivity hub: 17 industry connectionsNotable
Total Connections: 17.00
Scale
Market cap is $1.61B, above the global median of $1.18BNotable
Market cap (USD): 1,606,220,220.433Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Staidson (Beijing) Biopharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Natco Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Opm Biosciences Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Stoke Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Syndax Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Henan Lingrui Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Consun Pharmaceutical Group Limited
Tier 1ProductionApproval-Gated PipelineRule
BeBetter Med Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Rapport Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Forte Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule